Global Parkinson's Disease Treatments Sales Market Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Parkinson's Disease Treatments Sales Market Report 2024
Market Analysis and InsightsGlobal Parkinson's Disease Treatments Market
Parkinson’s disease is a central nervous system syndrome which affects the motor neuron, mainly characterized by rigidity, tremor, depression, dementia, and so on. Treatment for this disease is mostly symptomatic and almost no curative treatment alternatives are available.
Due to the COVID-19 pandemic, the global Parkinson's Disease Treatments market size is estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Dopamine Agonists accounting for % of the Parkinson's Disease Treatments global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospitals segment is altered to an % CAGR throughout this forecast period.
The United States Parkinson's Disease Treatments market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key players of Parkinson's Disease Treatments include GSK, Merck, Novartis, Teva, Boehringer Ingelheim, Impax, Abbvie, Bausch Health and Lundbeck, etc. In 2024, the global top five players have a share approximately % in terms of revenue.
In United States, in terms of revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Parkinson's Disease Treatments Scope and Market Size
The global Parkinson's Disease Treatments market is segmented by company, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Parkinson's Disease Treatments market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2018-2034.
Segment by Type
Dopamine Agonists
Levodopa
Glutamate Antagonist
Apomorphine
COMT Inhibitors Anticholinergics
MAO-B Inhibitors
Other Drugs
Hospitals
Healthcare Institutes
Others
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
GSK
Merck
Novartis
Teva
Boehringer Ingelheim
Impax
Abbvie
Bausch Health
Lundbeck
Sun Pharma
Wockhardt
Acadia
UCB
Parkinson’s disease is a central nervous system syndrome which affects the motor neuron, mainly characterized by rigidity, tremor, depression, dementia, and so on. Treatment for this disease is mostly symptomatic and almost no curative treatment alternatives are available.
Due to the COVID-19 pandemic, the global Parkinson's Disease Treatments market size is estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Dopamine Agonists accounting for % of the Parkinson's Disease Treatments global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospitals segment is altered to an % CAGR throughout this forecast period.
The United States Parkinson's Disease Treatments market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key players of Parkinson's Disease Treatments include GSK, Merck, Novartis, Teva, Boehringer Ingelheim, Impax, Abbvie, Bausch Health and Lundbeck, etc. In 2024, the global top five players have a share approximately % in terms of revenue.
In United States, in terms of revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Parkinson's Disease Treatments Scope and Market Size
The global Parkinson's Disease Treatments market is segmented by company, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Parkinson's Disease Treatments market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2018-2034.
Segment by Type
Dopamine Agonists
Levodopa
Glutamate Antagonist
Apomorphine
COMT Inhibitors Anticholinergics
MAO-B Inhibitors
Other Drugs
Segment by Application
Hospitals
Healthcare Institutes
Others
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
GSK
Merck
Novartis
Teva
Boehringer Ingelheim
Impax
Abbvie
Bausch Health
Lundbeck
Sun Pharma
Wockhardt
Acadia
UCB
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices